- Home
- NXN vs ATNM Comparison
NXN vs ATNM Comparison
Compare NXN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- ATNM
- Stock Information
- Founded
- NXN 1992
- ATNM 2000
- Country
- NXN United States
- ATNM United States
- Employees
- NXN N/A
- ATNM N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- ATNM Health Care
- Exchange
- NXN Nasdaq
- ATNM Nasdaq
- Market Cap
- NXN 45.3M
- ATNM 51.5M
- IPO Year
- NXN N/A
- ATNM N/A
- Fundamental
- Price
- NXN $11.56
- ATNM $1.36
- Analyst Decision
- NXN
- ATNM Strong Buy
- Analyst Count
- NXN 0
- ATNM 3
- Target Price
- NXN N/A
- ATNM $4.67
- AVG Volume (30 Days)
- NXN 9.7K
- ATNM 508.7K
- Earning Date
- NXN 01-01-0001
- ATNM 08-04-2025
- Dividend Yield
- NXN 4.23%
- ATNM N/A
- EPS Growth
- NXN N/A
- ATNM N/A
- EPS
- NXN 0.24
- ATNM N/A
- Revenue
- NXN N/A
- ATNM N/A
- Revenue This Year
- NXN N/A
- ATNM N/A
- Revenue Next Year
- NXN N/A
- ATNM N/A
- P/E Ratio
- NXN $48.42
- ATNM N/A
- Revenue Growth
- NXN N/A
- ATNM N/A
- 52 Week Low
- NXN $10.64
- ATNM $1.03
- 52 Week High
- NXN $12.45
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- NXN 53.45
- ATNM 43.05
- Support Level
- NXN $11.53
- ATNM $1.41
- Resistance Level
- NXN $11.68
- ATNM $1.95
- Average True Range (ATR)
- NXN 0.13
- ATNM 0.12
- MACD
- NXN 0.02
- ATNM -0.02
- Stochastic Oscillator
- NXN 49.23
- ATNM 11.93
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.